By Dr Benjamin Daniels

Journal articles

Brett J; Zoega H; Buckley NA; Daniels BJ; Elshaug AG; Pearson SA, 2018, 'Choosing wisely? Quantifying the extent of three low value psychotropic prescribing practices in Australia', BMC Health Services Research, 18, pp. 1009, http://dx.doi.org/10.1186/s12913-018-3811-5

Tan SYS; O’Neill S; Goldstein D; Ward RL; Daniels B; Vajdic CM, 2018, 'Predictors of care for patients with cancer of unknown primary site in three Australian hospitals', Asia Pacific Journal of Clinical Oncology, 14, pp. e512 - e520, http://dx.doi.org/10.1111/ajco.12815

Lopez D; Daniels B; Sanfilippo F; Pearson S; Martini A; Preen DB, 2018, 'Needs and priority areas for building capacity for working with linked data in the Australian pharmacoepidemiology workforce', International Journal of Population Data Science, 3, http://dx.doi.org/10.23889/ijpds.v3i4.733

Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA, 2018, 'Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016)', Breast Cancer Research and Treatment, 171, pp. 151 - 159, http://dx.doi.org/10.1007/s10549-018-4804-0

Daniels B; Girosi F; Tervonen H; Kiely BE; Lord SJ; Houssami N; Pearson SA, 2018, 'Adherence to prescribing restrictions for her2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016)', Plos One, 13, http://dx.doi.org/10.1371/journal.pone.0198152

Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA, 2018, 'Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001–2016)', Breast, 38, pp. 7 - 13, http://dx.doi.org/10.1016/j.breast.2017.11.007

Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE, 2018, 'ROR1 and ROR2 play distinct and opposing roles in endometrial cancer', Gynecologic Oncology, 148, pp. 576 - 584, http://dx.doi.org/10.1016/j.ygyno.2018.01.025

Daniels B; Kiely BE; Houssami N; Lord SJ; Dobbins T; Lu CY; Ward RL; Pearson SA, 2018, 'Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: A national population-based observational study (2006-2014)', British Journal of Cancer, 118, pp. 441 - 447, http://dx.doi.org/10.1038/bjc.2017.405

Harris CA; Daniels BJ; Ward RL; Pearson SA, 2017, 'Retrospective comparison of Australia’s Pharmaceutical Benefits Scheme claims data with prescription data in HER2 positive early breast cancer patients (2008-2012)', Public Health Research and Practice, 27, http://dx.doi.org/10.17061/phrp2751744

Brett J; Daniels B; Karanges EA; Buckley NA; Schneider C; Nassir A; McLachlan AJ; Pearson SA, 2017, 'Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study', British Journal of Clinical Pharmacology, 83, pp. 2581 - 2588, http://dx.doi.org/10.1111/bcp.13369

Brett J; Karanges EA; Daniels B; Buckley NA; Schneider C; Nassir A; Zoega H; McLachlan AJ; Pearson SA, 2017, 'Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure', Australian and New Zealand Journal of Psychiatry, 51, pp. 990 - 999, http://dx.doi.org/10.1177/0004867417721018

Daniels B; Lord SJ; Kiely BE; Houssami N; Haywood P; Lu CY; Ward RL; Pearson SA, 2017, 'Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: Protocol detailing observations in a whole of population cohort', BMJ Open, 7, http://dx.doi.org/10.1136/bmjopen-2016-014439

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2017, 'Validation of specificity of antibodies for immunohistochemistry: the case of ROR2', Virchows Archiv an International Journal of Pathology, 470, pp. 99 - 108, http://dx.doi.org/10.1007/s00428-016-2019-5

Ma SSQ; Henry CE; Llamosas E; Higgins R; Daniels B; Hesson LB; Hawkins NJ; Ward RL; Ford CE, 2016, 'Erratum to: Validation of specificity of antibodies for immunohistochemistry: the case of ROR2 (Virchows Archiv, (2016), 10.1007/s00428-016-2019-5)', Virchows Archiv, 469, pp. 717, http://dx.doi.org/10.1007/s00428-016-2036-4

Vajdic CM; Mayson E; Dodds AJ; O'Brien T; Wilcox L; Nivison-Smith I; Le Marsney R; Daniels B; Ashton LJ; Tan J; Bilmon I; Aarons D; Tran S; Gibson J; Johnston A; Greenwood M; Forbes M; Hertzberg M; Huang G; Spencer A; Muirhead J; Szer J; Mason K; Lewis I; To C; Durrant S; Western R; Cannell P; Buffery S; Oswald C; Nelson A; Shaw P; Pearson L; Tiedemann K; Scoyne M; Fraser C; Seljak J; Cole C; Rowland K; Gough H; Tapp H; Green N; Moa A; McRae J; Jenkins M; Hicks J; Chaplin K, 2016, 'Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Population-Based Cohort Study', Biology of Blood and Marrow Transplantation, 22, pp. 949 - 956, http://dx.doi.org/10.1016/j.bbmt.2016.01.027

Cairns R; Daniels B; Wood DA; Brett J, 2016, 'ADHD medication overdose and misuse: The NSW poisons information centre experience, 2004-2014', Medical Journal of Australia, 204, pp. 154 - 154.e7, http://dx.doi.org/10.5694/mja15.00791

Cairns R; Daniels B; Wood DA; Brett J, 2016, 'ADHD medication overdose and misuse: the NSW Poisons Information Centre experience, 2004-2014', The Medical journal of Australia, 204, pp. 154

Mellish L; Karanges EA; Litchfield MJ; Schaffer AL; Blanch B; Daniels BJ; Segrave A; Pearson SA, 2015, 'The Australian Pharmaceutical Benefits Scheme data collection: A practical guide for researchers', BMC Research Notes, 8, pp. 634, http://dx.doi.org/10.1186/s13104-015-1616-8

Blanch B; Daniels B; Litchfield M; Pearson SA, 2015, 'Looking forward and looking back: The balancing act in new drug user designs for pharmacoepidemiological research', Pharmacoepidemiology and Drug Safety, 24, pp. 1117 - 1119, http://dx.doi.org/10.1002/pds.3848

Ward RL; Laaksonen MA; van Gool K; Pearson SA; Daniels B; Bastick P; Norman R; Hou C; Haywood P; Haas M, 2015, 'Cost of cancer care for patients undergoing chemotherapy: The elements of cancer care study', Asia Pacific Journal of Clinical Oncology, 11, pp. 178 - 186, http://dx.doi.org/10.1111/ajco.12354

Nelson AS; Ashton LJ; Vajdic CM; Le Marsney RE; Daniels B; Nivison-Smith I; Wilcox L; Dodds AJ; O'Brien TA; Moa A, 2015, 'Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy', Leukemia, 29, pp. 441 - 447, http://dx.doi.org/10.1038/leu.2014.203

Henry C; Quadir A; Hawkins NJ; Jary E; Llamosas E; Kumar D; Daniels B; Ward RL; Ford CE, 2015, 'Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling', Journal of Cancer Research and Clinical Oncology, 141, pp. 243 - 254, http://dx.doi.org/10.1007/s00432-014-1824-y

Bilmon IA; Ashton LJ; Le Marsney RE; Dodds AJ; O'brien TA; Wilcox L; Nivison-Smith I; Daniels B; Vajdic CM; Dodds A; Tan J; Aarons D; Tran S; Gibson J; Johnston A; Greenwood M; Forbes M; Hertzberg M; Huang G; Spencer A; Muirhead J; Szer J; Mason K; Lewis I; To C; Durrant S; Western R; Cannell P; Buffery S; Oswald C; Nelson A; Shaw P; Pearson L; Tiedemann K; Scoyne M; Fraser C; Seljak J; Cole C; Rowland K; Gough H; Tapp H; Green N; Moa A; McRae J; Jenkins M; Hicks J; Chaplin K, 2014, 'Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: A population-based cohort study', Bone Marrow Transplantation, 49, pp. 691 - 698, http://dx.doi.org/10.1038/bmt.2014.13

Couttas TA; Kain N; Daniels B; Lim XY; Shepherd C; Kril J; Pickford R; Li H; Garner B; Don AS, 2014, 'Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis', Acta Neuropathologica Communications, 2, http://dx.doi.org/10.1186/2051-5960-2-9

Abuhusain HJ; Matin A; Qiao Q; Shen H; Kain N; Day BW; Stringer BW; Daniels B; Laaksonen MA; Teo C; McDonald KL; Don AS, 2013, 'A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis', Journal of Biological Chemistry, 288, pp. 37355 - 37364, http://dx.doi.org/10.1074/jbc.M113.494740

Conference Papers

Gisev N; Buizen L; Schaffer A; Daniels B; Pearson S-A; Dobbins T; Blyth F; Larney S; Currow DC; Wilson A; Degenhardt L, 2022, '| New South Wales, Long-term trajectories of prescription opioid use in New South Wales, Australia', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, pp. 371 - 372, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000859084401349&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Koch FC; Olivier J; Pearson S-A; Daniels B, 2022, 'A multivariate interrupted time series analysis assessing the impacts of half-pack sizes and increased access restrictions on publicly subsidized opioids in Australia', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY, pp. 541 - 542, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000859084402279&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Franchini F; Trapani K; Gillett P; Degeling K; Daniels B; Pearson S; Yang O; Zhang Y; Gibbs P; Ben S; McArthur G; Desai J; Fox S; IJzerman M, 2022, 'The PRIMCAT cohort study: Analysis of treatment utilisation, costs, and outcomes in Victoria for patients with cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 180 - 181

Tang M; Daniels B; Aslam M; Schaffer AL; Pearson S-A, 2021, 'Changes in systemic cancer therapy in Australia during the COVID-19 pandemic: a population-based study', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 69 - 70, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000717281500042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Havard A; Chidwick K; Daniels B; Thistlethwaite J; Myton R; Blogg S; Wall M; Quick L; Pollack A; Manski-Nankervis J-A, 2021, 'Validity of algorithms for identifying five chronic conditions in MedicineInsight, Australian national primary care data', in INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, OXFORD UNIV PRESS, ELECTR NETWORK, presented at World Congress of Epidemiology of the International-Epidemiological-Association (IEA), ELECTR NETWORK, 03 September 2021 - 06 September 2021, http://dx.doi.org/10.1093/ije/dyab168.270

Tang M; Schaffer A; Kiely B; Daniels B; Lee C; Simes J; Pearson S-A, 2021, 'Cardiac assessment in Australian patients receiving trastuzumab for HER2+early breast cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 30 - 30, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000050&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lord S; Daniels B; Kiely B; O'Connell D; Pearson S-A; Beith J; Bulsara M; Houssami N, 2021, 'Long-term risk of distant metastasis and post-metastasis survival for breast cancer: health record linkage study', in INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, OXFORD UNIV PRESS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000695815900386&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Liu D; Enriquez L; Daniels B; O'Mara T; Tang K; Ford C, 2021, 'Abstract PO042: ROR2 is epigenetically regulated in endometrial cancer', in Clinical Cancer Research, American Association for Cancer Research (AACR), pp. PO042 - PO042, http://dx.doi.org/10.1158/1557-3265.endomet20-po042

Daniels B; Kiely BE; Lord SJ; Houssami N; Pearson S-A, 2018, 'Abstract P2-12-01: Real-world use and outcomes of trastuzumab for HER2+ metastatic breast cancer in Australia: Analysis of the herceptin program, 2001-2015', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs17-p2-12-01

Harris C; Daniels B; Ward R; Pearson S-A, 2014, 'Do Pharmaceutical Claims Accurately Reflect Oncology Prescribing Practice: Evidence from an Australian HER2+Early Breast Cancer Cohort (HER2EBC)', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY-BLACKWELL, pp. 465 - 466, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342763600858&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Pearson S-A; Daniels B; Ward R, 2014, 'HER2 Positive Early Breast Cancer (HER2EBC): An Australian Patterns of Care Study', in PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, WILEY-BLACKWELL, pp. 468 - 468, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342763600863&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris CA; Ward RL; Daniels B; Pearson S, 2013, 'Do pharmaceutical claims accurately reflect oncology prescribing practice? Evidence from an Australian HER2+early breast cancer cohort ( HER2EBC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Diego, presented at ASCO's Quality Care Symposium, CA, San Diego, 01 November 2013 - 02 November 2013, http://dx.doi.org/10.1200/jco.2013.31.31_suppl.100

Harris CA; Pearson S; Daniels B; Srasuebkul P; Ward RL, 2013, 'HER2-positive early breast cancer (HER2EBC): An Australian pattern of care study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Diego, presented at ASCO's Quality Care Symposium, CA, San Diego, 01 November 2013 - 02 November 2013, http://dx.doi.org/10.1200/jco.2013.31.31_suppl.101

Conference Presentations

Daniels B, 2019, 'Identifying incident cancer cases in medicine dispensing claims: A validation study using Australia’s Pharmaceutical Benefits Scheme (PBS) data', presented at Asian Conference on Pharmacoepidemiology & Therapeutic Risk Management, 11 October 2019 - 13 October 2019

Daniels B, 2019, 'Validating administrative health data in Australia', presented at Asian Conference on Pharmacoepidemiology, Kyoto, Japan, 11 October 2019 - 13 October 2019

Daniels B, 2019, 'A Day in the Life: Prescription Medicine Use in Australia', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA, USA, 26 August 2019 - 28 August 2019

Daniels B; Pearson S, 2019, 'Understanding Treatment Pathways for HER2-Positive Metastatic Breast Cancer (HER2+MBC) Patients: Analysis Using Group-Based Trajectory Models (GBTM)', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czechia, 24 August 2019 - 26 August 2019

Daniels B; Pearson S, 2017, 'Real-world use and outcomes of trastuzumab for HER2+ metastatic breast cancer in Australia: Analysis of the Herceptin Program, 2001 – 2015', presented at San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 06 December 2017 - 10 December 2017

Daniels B; Pearson S, 2017, 'Patterns of care and outcomes for long-term survivors with HER2-positive metastatic breast cancer (HER2+MBC) starting trastuzumab: An Australian whole-of-population cohort study', presented at Clinical Oncology Society of Australia Annual Scientific Meeting, 13 November 2017 - 15 November 2017

Daniels B, 2017, 'Patterns of care for long-term surviving trastuzumab-treated patients with HER2-positive metastatic breast cancer (HER2+MBC): an Australian whole-of-population cohort study', presented at Asian Conference on Pharmacoepidemiology & Therapeutic Risk Management., 30 October 2017 - 01 November 2017

Daniels B; Pearson S, 2017, 'Did a policy to ease the prescribing restrictions for lapatinib as second-line HER2-positive metastatic breast cancer increase initiation rates?', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, QC, Canada, 26 August 2017 - 28 August 2018

Daniels B; Pearson S, 2016, 'Real-word use and outcomes of trastuzumab for metastatic breast cancer in Australia: Analysis of the Herceptin Program, 2001 – 2014', presented at Clinical Oncology Society of Australia Annual Scientific Meeting, Gold Coast, QLD, 15 November 2016 - 17 November 2016

Daniels B; Pearson S, 2016, 'Tracking trastuzumab (H) therapy in early- through late-stage HER2-positive breast cancer (HER2+BC) in Australia: A national, retrospective cohort study', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, 26 August 2016 - 29 August 2016

Daniels B; Pearson S, 2016, 'Opportunities for post-market surveillance of high cost medicines in Australia: Observing trastuzumab-treated women from early- through late-stage HER2-positive breast cancer (HER2+BC)', presented at International Population Data Linkage Conference, Swansea, Wales, UK, 23 August 2016 - 26 August 2016, http://dx.doi.org/10.23889/ijpds.v1i1.142

Daniels B, 2015, 'Relative misclassification (RM) of new medicine users based on look-back period', presented at Australian Population Health Congress, 07 September 2015 - 09 September 2015

Back to profile page